Trial
NCT00671801
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
M.D. Anderson Cancer Center
Collaborators
Celgene
Condition
Malignant Gliomas
Intervention
Irinotecan
Why stopped
Toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-11-13